Spots Global Cancer Trial Database for A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Official Title: A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas.
Study ID: NCT04464798
Conditions
Study Description
Brief Summary: This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and have at least one measurable lesion according to Lugano 2014 classification. Study will consist of two parts: Part 1 (Dose Escalation) which will be followed by Part 2 (Dose Expansion).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 106, Phoenix, Arizona, United States
Local Institution - 105, Lake Mary, Florida, United States
Local Institution - 102, Rochester, Minnesota, United States
Local Institution - 100, New York, New York, United States
University of Rochester Cancer Center, Rochester, New York, United States
Local Institution - 103, Nashville, Tennessee, United States
Local Institution - 203, Creteil, , France
Local Institution - 200, Lillie Cedex, , France
Local Institution - 201, Montpellier CEDEX 5, , France
Local Institution - 202, Nantes cedex 1, , France
Local Institution - 204, Paris, , France
Local Institution - 205, Pessac, , France
Local Institution - 401, Berlin, , Germany
Local Institution - 402, Leipzig, , Germany
Local Institution - 403, Munster, , Germany
Local Institution - 404, Wuerzburg, , Germany
Local Institution - 300, Brescia, , Italy
Local Institution - 303, Milano, , Italy
Local Institution - 301, Pavia, , Italy
Local Institution - 302, Verona, , Italy
Local Institution - 502, Seoul, , Korea, Republic of
Local Institution - 501, Seoul, , Korea, Republic of
Local Institution - 500, Seoul, , Korea, Republic of
Local Institution - 600, Niaosong District Kaohsiung City, , Taiwan
Local Institution - 601, Taoyuan City, , Taiwan
Local Institution - 602, Taoyuan City, , Taiwan
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
